Patents Assigned to Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt
-
Patent number: 11733236Abstract: The present invention relates to the use of the biomarker Flattop (Fltp) for distinguishing mature ? cells from immature progenitor ? cells. The present invention further relates to a method for distinguishing a mature ? cell from an immature progenitor ? cell, the method comprising: determining the presence or absence of the biomarker Flattop (Fltp) in a ? cell; wherein the presence of Fltp in the cell indicates that the cell is a mature ? cell and wherein the absence of Fltp in the cell indicates that the cell is an immature progenitor ? cell. Furthermore, the present invention relates to a method of identifying a compound suitable for differentiating immature progenitor ? cells into mature ? cells as well as to a method of identifying a compound suitable for preventing the de-differentiating of mature ? cells. The present invention additionally relates to a method of differentiating immature progenitor ? cells into mature ? cells as well as to a method of preventing de-differentiating of mature ? cells.Type: GrantFiled: November 14, 2019Date of Patent: August 22, 2023Assignee: Helmholtz Zentrum München—Deutsches Forschungszentrum Für Gesundheit Und Umwelt (GMBH)Inventors: Heiko Lickert, Adriana Migliorini, Moritz Gegg, Erik Bader
-
Patent number: 11530273Abstract: The present invention relates to improved anti-CD73 antibodies which, in comparison to prior art anti-CD73 antibodies bind to a membrane-bound form of CD73 protein having cancer-promoting role and inhibit its enzymatic activity, while essentially not inhibiting a soluble form of CD73 protein involved in cardioprotection. The present invention further relates to methods of generation of such specific anti-CD73 antibodies and uses thereof including uses as medicaments and in methods for treatment, amelioration, prophylaxis and diagnostics of cancer.Type: GrantFiled: May 23, 2018Date of Patent: December 20, 2022Assignee: Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventors: Reinhard Zeidler, Bettina Von Neubeck, Regina Feederle, Stefanie Hauck
-
Patent number: 11365237Abstract: The present invention relates to fusion proteins comprising (a) an extracellular domain containing a polypeptide derived from PD-1 or CD40L at its N-terminus; (b) a transmembrane domain; and (c) an intracellular domain containing a polypeptide derived from 4-1BB or CD28 at its C-terminus. Also, fusion proteins with CD28 at the N-terminus and CD40L at the C-terminus are envisaged. The present invention also relates to nucleic acid molecules encoding such fusion proteins, vectors containing such nucleic acid molecules, and host cells containing such vectors. The present invention further relates to methods for producing such host cells. Finally, the present invention relates to pharmaceutical compositions comprising such fusion proteins, nucleic acid molecules, vectors, and/or host cells, particularly for treating diseases or disorders associated with PD-1/PD-L2 or CD40 binding and/or PD-L1/PD-L2 or CD40 expression such as cancer and chronic viral infection.Type: GrantFiled: March 23, 2017Date of Patent: June 21, 2022Assignee: HELMHOLTZ ZENTRUM MUENCHEN—DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT (GMBH)Inventors: Elfriede Noessner, Ramona Schlenker, Stephan Weisz
-
Patent number: 11161902Abstract: In general, the present invention relates to the field of (bio-)medicine and in particular to various metabolic diseases. Specifically, the invention provides means and methods for diagnosing, monitoring and predicting the risk for developing metabolic diseases. The invention uses exosomes as biomarkers for the aforementioned purposes. Moreover, an antibody of the present invention capable of specifically recognizing tissue-specific exosomes is also provided.Type: GrantFiled: May 9, 2017Date of Patent: November 2, 2021Assignee: Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (GmbH)Inventors: Kerstin Stemmer, Matthias Tschöp, Michaela Bauer, Reinhard Zeidler, Regina Feederle
-
Patent number: 11149289Abstract: The present invention relates to a nucleic acid molecule encoding (I) a polypeptide having the activity of an endonuclease, which is (a) a nucleic acid molecule encoding a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 2; (c) a nucleic acid molecule encoding an endonuclease, the amino acid sequence of which is at least 70% identical to the amino acid sequence of SEQ ID NO: 1; (d) a nucleic acid molecule comprising or consisting of a nucleotide sequence which is at least 50% identical to the nucleotide sequence of SEQ ID NO: 2; (e) a nucleic acid molecule which is degenerate with respect to the nucleic acid molecule of (d); or (f) a nucleic acid molecule corresponding to the nucleic acid molecule of any one of (a) to (e) wherein T is replaced by U; (II) a fragment of the polypeptide of (I) having the activity of an endonuclease.Type: GrantFiled: April 23, 2018Date of Patent: October 19, 2021Assignee: Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventor: Ralf Kühn
-
Patent number: 11001591Abstract: The invention relates to compounds which are suitable for the treatment of cancer, an immune disease, Parkinson's disease, Cardiac Hypertrophy or Type-2 diabetes and to pharmaceutical compositions containing such compounds. The invention further relates to a kit of parts comprising such compounds.Type: GrantFiled: March 9, 2020Date of Patent: May 11, 2021Assignee: HELMHOLTZ ZENTRUM MUENCHEN—DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)Inventors: Kamyar Hadian, Jara Kerstin Brenke, Oliver Plettenburg, Gerrit Juerjens
-
Patent number: 11000568Abstract: The present invention relates to the field of (bio-)medicine, and more particularly to the treatment of copper-related diseases. Novel means and methods for depleting (excess) copper from organs and/or the circulation are provided. Agents with a high copper binding affinity and stabilized forms thereof are provided, as well as a novel treatment regimen. The means and methods of the present invention are particularly useful for treatment of Wilson Disease, but also for treatment of other conditions.Type: GrantFiled: December 16, 2016Date of Patent: May 11, 2021Assignees: HELMHOLTZ ZENTRUM MÜNCHEN—DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH), IOWA STATE UNIVERSITY RESEARCH FOUNDATION, THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Hans Zischka, Josef Lichtmannegger, Alan Angelo Dispirito, Jeremy David Semrau
-
Patent number: 10912827Abstract: The present invention relates to an improved recombinant vaccination vector for the treatment or vaccination against hepatitis B virus (HBV) as well as pharmaceutical compositions or vaccines comprising said recombinant vaccination vector. The present invention also relates to a recombinant vaccination vector for use in a method of vaccination against HBV, as well as kits comprising a vaccine comprising the recombinant vaccination vector.Type: GrantFiled: January 12, 2017Date of Patent: February 9, 2021Assignee: HELMHOLTZ ZENTRUM MÜNCHEN—DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)Inventors: Ulrike Protzer, Tanja Bauer, Anna Kosinska, Martin Mueck-Haeusl
-
Patent number: 10900018Abstract: The present invention is in the field of stem cell biology, in particular in the field of developmental and regenerative biology. The invention generally relates to a method of generating cells capable of differentiating to a multicellular organoid unit that morphologically and/or functionally resembles the terminal ductal-lobular unit. More precisely, said cells are generated by dissociating mammary epithelial tissue, thereby gaining cells and culturing said cells in presence of a compound which elevates cAMP levels in a collagen gel. Under said culturing conditions said cells form a multicellular organoid unit facilitating to obtain a breast stem cell by isolating a single cell from said multicellular organoid unit. The present invention also relates to enriching said cells and differentiating them to a multicellular organoid that morphologically and/or functionally resembles the terminal ductal-lobular unit and use of said cells or said multicellular organoid in testing a compound.Type: GrantFiled: April 28, 2016Date of Patent: January 26, 2021Assignee: Helmholtz Zentrum München—Deutsches Forschungszentrum Für Gesundheit Und Umwelt (GMBH)Inventors: Christina H. Scheel, Jelena R. Linnemann, Lisa K. Meixner, Haruko Miura
-
Patent number: 10752881Abstract: The present invention comprises methods and compositions related to trans-differentiating differentiated cells, the methods comprising bringing said cells into contact with a polypeptide or a nucleic acid encoding said polypeptide.Type: GrantFiled: January 29, 2015Date of Patent: August 25, 2020Assignee: Helmholtz Zentrum München—Deutsches Forschungszentrum Für Gesundheit Und Umwelt (GMBH)Inventors: Sergio Gascón Jiménez, Magdalena Götz
-
Patent number: 10669278Abstract: The invention relates to compounds which are suitable for the treatment of cancer, an immune disease, Parkinson's disease, Cardiac Hypertrophy or Type-2 diabetes and to pharmaceutical compositions containing such compounds. The invention further relates to a kit of parts comprising such compounds.Type: GrantFiled: September 18, 2017Date of Patent: June 2, 2020Assignee: HELMHOLTZ ZENTRUM MUENCHEN—DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)Inventors: Kamyar Hadian, Jara Kerstin Brenke, Oliver Plettenburg, Gerrit Juerjens
-
Patent number: 10195267Abstract: In a first aspect, the present invention relates to the use of a TLR 9 agonist and/or a TLR 4 agonist in a prophylactic or therapeutic vaccine. According to the present vaccination strategy, the TLR 9 agonist and/or TLR 4 agonist is adapted or designed for use as a multiplying jump agent to enhance numbers and functionality of CD8 T cells in a prime-jump vaccination strategy for jump T cell expansion. In particular, the TLR 9 agonist and/or TLR 4 agonist is used as a component to be administered after priming of the individual to be vaccinated. The vaccination strategy is particularly useful against acute and chronic infections with intracellular pathogens or for anti-tumor vaccination. In another aspect, the present invention relates to a kit of part containing a prime agent and a multiplying jump agent according to the present invention.Type: GrantFiled: February 25, 2014Date of Patent: February 5, 2019Assignees: KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITÄT MÜNCHEN, TECH UNIVERSITÄT MÜNCHEN, HELMHOLTZ ZENTRUM MÜNCHEN—DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELTInventors: Percy Knolle, Li-Rung Huang, Mathias Heikenwälder, Ulrike Protzer
-
Patent number: 10072273Abstract: The present invention relates to a nucleic acid molecule comprising or consisting of a nucleic acid sequence encoding the vesicular stomatitis virus envelope glycoprotein (VSV-G) linked to a (poly)peptide comprising or consisting of a cell membrane-binding domain, said nucleic acid sequence comprising in 5? to 3? direction (a) a first sequence segment encoding an endoplasmic reticulum (ER) signal sequence; (b) a second sequence segment encoding said (poly)peptide comprising or consisting of a cell membrane-binding domain; (c) a third sequence segment encoding a linker; and (d) a fourth sequence segment encoding said VSV-G. Further, the invention relates to a vector comprising the nucleic acid molecule of the invention, a host cell comprising said vector or nucleic acid molecule, the polypeptide encoded by said nucleic acid molecule and a method of producing the polypeptide encoded by said nucleic acid molecule.Type: GrantFiled: January 9, 2015Date of Patent: September 11, 2018Assignees: Helmholtz Zentrum München—Deutsches Forschungszentrum Für Gesundheit Und Umwelt (GMBH), Sirion Biotech GmbHInventors: Nata{hacek over (s)}a Anastasov, Ines Höfig, Christian Thirion
-
Patent number: 10059767Abstract: The present invention relates to a polypeptide comprising (a) a first set of six complementarity determining regions (CDRs) configured to bind a first antigen; and (b) (ba) a second set of six CDRs configured to bind a second antigen; or (bb) a ligand capable of binding to a second antigen; wherein (i) said first antigen is selected from Hepatitis B virus (HBV) small surface antigen; HBV medium surface antigen; and HBV large surface antigen; and (ii) said second antigen is selected from surface antigens presented by immune effector cells such as natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). Also provided are compositions for use in a method of treating or preventing HBV infection and/or a condition caused by said HBV infection, said condition caused by said HBV infection being selected from liver cirrhosis and hepatocellular carcinoma.Type: GrantFiled: September 16, 2014Date of Patent: August 28, 2018Assignees: Helmholtz Zentrum München—Deutsches Forschungszentrum Für Gesundheit Und Umwelt (GMBH), Deutsches KrebsforschungszentrumInventors: Ulrike Protzer, Felix Bohne, Frank Momburg, Gerhard Moldenhauer
-
Patent number: 9718811Abstract: The present invention relates to the (S)-enantiomer of mepazine, its applicability in therapy, a pharmacological composition comprising (S)-mepazine, and processes for the preparation of (S)-mepazine and one of its intermediates.Type: GrantFiled: June 25, 2014Date of Patent: August 1, 2017Assignees: Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Ludwig-Maximilians—Universität MünchenInventors: Daniel Krappmann, Daniel Nagel, Florian Schlauderer, Katja Lammens, Karl-Peter Hopfner, Robert A. Chrusciel, Dale L. Kling
-
Patent number: 9410134Abstract: The present invention relates to a nucleic acid molecule encoding (I) a polypeptide having the activity of an endonuclease, which is (a) a nucleic acid molecule encoding a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 2; (c) a nucleic acid molecule encoding an endonuclease, the amino acid sequence of which is at least 70% identical to the amino acid sequence of SEQ ID NO: 1; (d) a nucleic acid molecule comprising or consisting of a nucleotide sequence which is at least 50% identical to the nucleotide sequence of SEQ ID NO: 2; (e) a nucleic acid molecule which is degenerate with respect to the nucleic acid molecule of (d); or (f) a nucleic acid molecule corresponding to the nucleic acid molecule of any one of (a) to (e) wherein T is replaced by U; (II) a fragment of the polypeptide of (I) having the activity of an endonuclease.Type: GrantFiled: June 6, 2012Date of Patent: August 9, 2016Assignee: Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und UmweltInventor: Ralf Kühn